RSS

alpha-synuclein antibody

A collaboration has been announced between AstraZeneca and Takeda Pharmaceutical Company for the development and commercialisation of an alpha-synuclein antibody, MEDI1341, as a potential treatment for Parkinson’s disease. more

News